Glioblastoma Multiforme Treatment (GBM) Market Insights, 2021-2028

Glioblastoma Multiforme Treatment (GBM) Market (Treatment: Radiation Therapy, Chemotherapy [Temozolomide, Bevacizumab, Carmustine, and Other Types of Chemotherapy], and Other Treatments; and End-user: Hospitals, Ambulatory Surgical Centers, and Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Glioblastoma Multiforme (GBM) Treatment Market Outlook 2028

  • The global glioblastoma multiforme (GBM) treatment market was valued at US$ US$ 1.61 Bn in 2020
  • It is estimated to expand at a CAGR of 8.1% from 2021 to 2028
  • The global glioblastoma multiforme (GBM) treatment market is expected to reach the value of US$ 3.72 Bn by the end of 2028

Analysts’ Viewpoint Glioblastoma Multiforme (GBM) Treatment Market Scenario

Since active COVID-19 infection cases are declining in most countries except for regions such as Shanghai in China, participants in the glioblastoma multiforme (GBM) treatment market are witnessing an uptick in market growth. However, poor medical outcomes in GBM patients are discouraging patients to seek medical treatment. Hence, market players should offer better reimbursement packages to individuals to encourage GBM patients for seeking medical treatment. Healthcare companies should increase awareness about early diagnosis of GBM through marketing in order to reduce its severity in potential patients. In addition, healthcare companies should invest in R&D by seeking funds from cancer organizations to develop better treatment alternatives in chemo, drugs, and radiotherapy to improve patient outcomes.

Positive Regulatory Framework in U.S. Benefitting Healthcare Companies

Mature healthcare markets such as the U.S. in North America are creating stable revenue streams for market stakeholders. North America is projected to be a highly lucrative region for the glioblastoma multiforme (GBM) treatment market throughout the assessment tenure. Major healthcare companies are bullish on investments in R&D for increasing the availability of treatment options across the region.

Leading-edge and advanced healthcare infrastructure in the U.S. has aided in the development of drug repurposing for the treatment of glioblastoma multiforme. Moreover, favorable regulatory environment is a key factor propelling the glioblastoma multiforme (GBM) treatment market in North America. A positive legal and regulatory environment facilitates the development and early acceptance of GBM medications.

Request a sample to get extensive insights into the Brazil Parenteral Nutrition Market

Relaxation in COVID-19 Restrictions Increasing Footfalls in Healthcare Facilities

Since glioblastoma multiforme is a potentially life-threatening autoimmune disorder, healthcare stakeholders in the glioblastoma multiforme (GBM) treatment market are striving to ensure the availability of radiation therapy and chemotherapy amid the ongoing COVID-19 pandemic. Pharmaceutical companies have been working at breakneck speeds to maintain robust supply for life-altering therapeutics, medications, and other drugs at hospitals, ambulatory surgical centers, and clinics.

Healthcare companies are taking data-driven decisions before investing in R&D for drug development and other therapeutic innovations. They are capitalizing on government stimulus packages in order to keep economies going. Relaxations in pandemic related restrictions are helping to increase footfalls in healthcare facilities.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Funding from Healthcare Organizations Hold Potentials for Better GBM Treatment Outcomes

The global glioblastoma multiforme (GBM) treatment market is increasingly sensitive toward R&D, manufacturing costs, as well as market price, since the market is challenged with high morbidity and mortality rates. For small- or medium-scale healthcare companies, glioblastoma multiforme treatment research & development requires significant amount of resources and capital. Such trends are inhibiting market growth.

Glioblastoma multiforme (GBM) treatment is a commonly found cancer but it is associated with poor medical outcomes, owing to its aggressive nature for metastasis in the human body. These findings are triggering the need for high investment in R&D activities. Hence, uncertainty over expected profit deters companies from entering the market. Thus, companies should work closely with major healthcare organizations to increase funding for R&D.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Traditional Chinese Herbal Medicine for Face-care Market

Surging Demand for Glioblastoma Multiforme Treatment to Propel Global Market

The rise in prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes is expected to drive the glioblastoma multiforme (GBM) treatment market. However, it has been found that survival rate of patients suffering from GBM is relatively poor.

Very few patients survive for 2.5 to 5 years following diagnosis. According to the data published by the Centers for Disease Control and Prevention (CDC), a national public health agency of the U.S., 90% of the adult patients with GBM die within 24 months after diagnosis. Moreover, the incidence of GBM ranges from 0.59 to 5 per 100,000 individuals, and this rate is increasing in multiple countries across the globe. The figures above indicate that the demand for treatment is likely to increase exponentially, which, in turn, is projected to augment the global glioblastoma multiforme (GBM) treatment market.

R&D Helps Accelerate Treatment Options for Glioblastoma Multiforme

Companies in the glioblastoma multiforme (GBM) treatment market are expected to join forces with researchers from universities to fast-track the drug development of glioblastoma. Such collaborations are encouraging international cancer organizations to fund R&D activities. Pharmaceutical companies are entering into cooperation agreement with research centers for the clinical development of radiopharmaceutical therapy, for the treatment of glioblastoma multiforme.

Innovative healthcare therapeutics companies are announcing the early results from phase 1 trials of its glioblastoma multiforme treatment alternative. The treatment was developed using peptide inhibitor to fight against recurrent high-grade gliomas.

Glioblastoma Multiforme Treatment (GBM) Market: Overview

  • According to Transparency Market Research’s latest report on the global glioblastoma multiforme treatment (GBM) market for the historical period 2017–2019 and forecast period from 2021 to 2028, increase in research funding, rise in government support, improved regulatory framework, technological advancements, and surge in prevalence of chronic glioblastoma multiforme disease are projected to drive the global glioblastoma multiforme treatment (GBM) market during the forecast period

Increase in Approvals for Glioblastoma Multiforme Treatment: Key Driver

  • Glioblastoma Multiforme (GBM) is the most common and aggressive form of primary brain cancer
  • Increase in approvals for novel and combination therapies is projected to propel the global glioblastoma multiforme treatment (GBM) market during the forecast period
  • In December 2021, Sapience Therapeutics, Inc., a biotech firm specialized in developing novel therapeutics to treat oncology indications, received the U.S. Food and Drug Administration's (FDA) fast track designation for ST101. ST101 is a peptide inhibitor of C/EBPβ for the treatment of patients with glioblastoma multiforme (GBM). In June 2019, the FDA granted Pfizer’s Zirabev, a mAb biosimilar of the reference product, Avastin, for the treatment of glioblastoma, colorectal cancer, and others diseases. In January 2020, the company announced the launch of the product in the U.S.

Surge in Incidence of Glioblastoma Multiforme: Major Driver

  • Rise in awareness about chemotherapy treatment is projected to drive the global glioblastoma multiforme (GBM) treatment market during the forecast period
  • Increase in cases of brain and other nervous system cancers across the world is another factor anticipated to propel the glioblastoma multiforme (GBM) treatment market. Several companies emphasize on inventing generic products for the treatment of glioblastoma to strengthen their presence across the developing & developed countries and maintain their competitive advantage. Moreover, increase in funding and grants for companies engaged in research activities related to glioblastoma are expected to augment the global market during the forecast period.

High Cost of Glioblastoma Multiforme Treatment R&D and Manufacturing to Hamper Market

  • The global glioblastoma multiforme treatment (GBM) market is concerned about R&D and manufacturing costs as well as market price. For a developing organization, glioblastoma multiforme treatment research & development requires significant resources.
  • Glioblastoma multiforme treatment (GBM) is a niche segment and requires high investment. Hence, uncertainty over expected profit deters companies from entering the market.

Glioblastoma Multiforme Treatment (GBM) Market: Competition Landscape

  • This report profiles major players in the global glioblastoma multiforme treatment (GBM) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global glioblastoma multiforme treatment (GBM) market is quite competitive, with the top 10 players accounting for major share of the market and companies focusing on research & development to produce better pharmaceutical and vaccine products for the existing diseases
  • Leading players operating in the global glioblastoma multiforme treatment (GBM) market are
    • AbbVie Inc.
    • Activartis GmbH
    • Agenus Inc.
    • Arog Pharmaceuticals Inc.
    • Bristol-Myers Squibb Company
    • Cavion LLC
    • Celldex Therapeutics Inc.
    • CTI BioPharma Corporation (formerly Cell Therapeutics Inc.)
    • Cortice Biosciences Inc.
    • Eisai Co. Ltd.
    • Exelixis Inc.
    • F. Hoffmann-La Roche Ltd.
    • Peregrine Pharmaceuticals Inc.
    • OncoSynergy
    • Merrimack Pharmaceuticals Inc.

Glioblastoma Multiforme Treatment (GBM) Market: Key Developments

  • Key players in the global glioblastoma multiforme treatment (GBM) market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to drive the global glioblastoma multiforme treatment (GBM) market.
  • A few expansion strategies adopted by players operating in the global glioblastoma multiforme treatment (GBM) market are:
  • In February 2022, a researcher from the University of Alabama at Birmingham (UAB) Department of Pathology received a US$ 3.09 Mn R01 grant from the National Cancer Institute in order to fast-track the drug development for glioblastoma
  • In January 2022, ITM Isotope Technologies Munich SE, a Germany-based pharmaceutical company, entered into cooperation agreement with Helmholtz Zentrum München, the German Research Center for Environmental Health for the clinical development of radiopharmaceutical therapy, for the treatment of glioblastoma multiforme
  • In November 2021, OX2 Therapeutics, Inc., an innovative healthcare therapeutics company, announced the early results from phase 1 trials of its glioblastoma multiforme treatment (GBM). The treatment was developed using peptide inhibitor to fight against recurrent high-grade gliomas.
  • The report on the global glioblastoma multiforme treatment (GBM) market discusses individual strategies followed by company profiles of manufacturers of glioblastoma multiforme treatment (GBM) devices. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global glioblastoma multiforme treatment (GBM) market.

Glioblastoma Multiforme Treatment (GBM) Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 1.61 Bn

Market Forecast Value in 20231

US$ 3.72 Bn

Growth Rate (CAGR)

8.1%

Forecast Period

2021–2028

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Treatment
    • Radiation Therapy
    • Chemotherapy
      • Temozolomide
      • Bevacizumab
      • Carmustine
      • Other Types of Chemotherapy
    • Other Treatments
  • End-user
    • Hospitals
    • Ambulatory Surgical Centers
    • Clinics

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Merck & Co., Inc.
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Amgen, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Arbor Pharmaceuticals, LLC
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics, Inc.
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Glioblastoma Multiforme Treatment (GBM) Market – Segmentation

Treatment
  • Radiation Therapy
  • Chemotherapy
    • Temozolomide
    • Bevacizumab
    • Carmustine
    • Other Types of Chemotherapy
  • Other Treatments
End-user
  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of glioblastoma multiforme (GBM) treatment market?

Glioblastoma multiforme (GBM) treatment market is expected to reach the value of US$ 3.72 Bn by the end of 2028

What is the anticipated CAGR of the glioblastoma multiforme (GBM) treatment market in the forecast period?

Glioblastoma multiforme (GBM) treatment market is estimated to expand at a CAGR of 8.1% from 2021 to 2028

What are the key driving factors for the growth of the glioblastoma multiforme (GBM) treatment market?

Glioblastoma multiforme (GBM) treatment market is driven by rise in prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes

Which region is expected to project the highest market share in the global glioblastoma multiforme (GBM) treatment market?

North America accounted for the largest share of the global glioblastoma multiforme (GBM) treatment market

Who are the key players in the global glioblastoma multiforme (GBM) treatment market?

Key players in the global glioblastoma multiforme (GBM) treatment market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Glioblastoma Multiforme Treatment (GBM) Market 

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, 2017–2028

    5. Key Insights

        5.1. Regulatory Scenario, by Region/globally

        5.2. Key Mergers & Acquisitions 

        5.3. Technological Advancements

        5.4. COVID-19 Pandemics Impact on Industry

    6. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Treatment

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Treatment, 2017–2028

            6.3.1. Radiation Therapy

            6.3.2. Chemotherapy

                6.3.2.1. Temozolomide

                6.3.2.2. Bevacizumab

                6.3.2.3. Carmustine

                6.3.2.4. Other Types of Chemotherapy

            6.3.3. Other Treatments

        6.4. Market Attractiveness Analysis, by Treatment

    7. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by End-user 

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by End-user, 2017–2028

            7.3.1. Hospitals

            7.3.2. Ambulatory Surgical Centers

            7.3.3. Clinics

        7.4. Market Attractiveness Analysis, By End-user 

    8. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region

            8.2.1. North America  

            8.2.2. Europe 

            8.2.3. Asia Pacific 

            8.2.4. Latin America 

            8.2.5. Middle East & Africa 

        8.3. Market Attractiveness Analysis, By Country/Region

    9. North America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Treatment, 2017–2028

            9.2.1. Radiation Therapy

            9.2.2. Chemotherapy

                9.2.2.1. Temozolomide

                9.2.2.2. Bevacizumab

                9.2.2.3. Carmustine

                9.2.2.4. Other Types of Chemotherapy

        9.3. Market Value Forecast, by End-user, 2017–2028

            9.3.1. Hospitals

            9.3.2. Ambulatory Surgical Centers

            9.3.3. Clinics

        9.4. Market Value Forecast, by Country, 2017–2028

            9.4.1. U.S. 

            9.4.2. Canada 

        9.5. Market Attractiveness Analysis 

            9.5.1. By Treatment

            9.5.2. By End-user 

            9.5.3. By Country

    10. Europe Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Treatment, 2017–2028

            10.2.1. Radiation Therapy

            10.2.2. Chemotherapy

            10.2.3. Temozolomide

            10.2.4. Bevacizumab

            10.2.5. Carmustine

            10.2.6. Other Types of Chemotherapy                  

            10.2.7. Other Treatments

        10.3. Market Value Forecast, by End-user, 2017–2028

            10.3.1. Hospitals

            10.3.2. Ambulatory Surgical Centers

            10.3.3. Clinics

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2028

            10.4.1. Germany 

            10.4.2. U.K. 

            10.4.3. France 

            10.4.4. Italy 

            10.4.5. Spain 

            10.4.6. Rest of Europe 

        10.5. Market Attractiveness Analysis 

            10.5.1. By Treatment

            10.5.2. By End-user 

            10.5.3. By Country/Sub-region

    11. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Treatment, 2017–2028

            11.2.1. Radiation Therapy

            11.2.2. Chemotherapy

                11.2.2.1. Temozolomide

                11.2.2.2. Bevacizumab

                11.2.2.3. Carmustine

                11.2.2.4. Other Types of Chemotherapy

            11.2.3. Other Treatments

        11.3. Market Value Forecast, by End-user, 2017–2028

            11.3.1. Hospitals

            11.3.2. Ambulatory Surgical Centers

            11.3.3. Clinics

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2028

            11.4.1. China 

            11.4.2. Japan 

            11.4.3. India 

            11.4.4. Australia & New Zealand 

            11.4.5. Rest of Asia Pacific 

        11.5. Market Attractiveness Analysis 

            11.5.1. By Treatment

            11.5.2. By Drug Class

            11.5.3. By End-user 

            11.5.4. By Country/Sub-region

    12. Latin America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Treatment, 2017–2028

            12.2.1. Radiation Therapy

            12.2.2. Chemotherapy

                12.2.2.1. Temozolomide

                12.2.2.2. Bevacizumab

                12.2.2.3. Carmustine

                12.2.2.4. Other Types of Chemotherapy 

            12.2.3. Other Treatments

        12.3. Market Value Forecast, by End-user, 2017–2028

            12.3.1. Hospitals

            12.3.2. Ambulatory Surgical Centers

            12.3.3. Clinics

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2028

            12.4.1. Brazil 

            12.4.2. Mexico 

            12.4.3. Rest of Latin America 

        12.5. Market Attractiveness Analysis 

            12.5.1. By Treatment

            12.5.2. By Drug Class

            12.5.3. By End-user 

            12.5.4. By Country/Sub-region

    13. Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Treatment, 2017–2028

            13.2.1. Radiation Therapy

            13.2.2. Chemotherapy

                13.2.2.1. Temozolomide

                13.2.2.2. Bevacizumab

                13.2.2.3. Carmustine

                13.2.2.4. Other Types of Chemotherapy

            13.2.3. Other Treatments

        13.3. Market Value Forecast, by End-user, 2017–2028

            13.3.1. Hospitals

            13.3.2. Ambulatory Surgical Centers

            13.3.3. Clinics

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2028

            13.4.1. GCC Countries 

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa 

        13.5. Market Attractiveness Analysis 

            13.5.1. By Treatment

            13.5.2. By Drug Class

            13.5.3. By End-user 

            13.5.4. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competition Matrix (by tier and size of companies)

        14.2. Market Share Analysis, by Company, 2020

        14.3. Company Profiles

            14.3.1. Merck & Co., Inc.

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Financial Analysis

                14.3.1.3. Growth Strategies

                14.3.1.4. SWOT Analysis

            14.3.2. F. Hoffmann-La Roche Ltd.

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Financial Analysis

                14.3.2.3. Growth Strategies

                14.3.2.4. SWOT Analysis

            14.3.3. Pfizer Inc.

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Financial Analysis

                14.3.3.3. Growth Strategies

                14.3.3.4. SWOT Analysis

            14.3.4. Amgen, Inc. 

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Financial Analysis

                14.3.4.3. Growth Strategies

                14.3.4.4. SWOT Analysis

            14.3.5. Teva Pharmaceutical Industries Ltd.

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Financial Analysis

                14.3.5.3. Growth Strategies

                14.3.5.4. SWOT Analysis

            14.3.6. Sun Pharmaceutical Industries Ltd.

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Financial Analysis

                14.3.6.3. Growth Strategies

                14.3.6.4. SWOT Analysis 

            14.3.7. Arbor Pharmaceuticals, LLC

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Financial Analysis

                14.3.7.3. Growth Strategies

                14.3.7.4. SWOT Analysis

            14.3.8. Amneal Pharmaceuticals

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Financial Analysis

                14.3.8.3. Growth Strategies

                14.3.8.4. SWOT Analysis

            14.3.9. Karyopharm Therapeutics, Inc.

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Financial Analysis

                14.3.9.3. Growth Strategies

                14.3.9.4. SWOT Analysis

            14.3.10. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Financial Analysis

                14.3.10.3. Growth Strategies

                14.3.10.4. SWOT Analysis

    List of Tables

    TABLE 1: Market Snapshot: Global Glioblastoma Multiforme Treatment (GBM) Market

    TABLE 2: Global Prevalence of Glioblastoma Multiforme worldwide

    TABLE 3: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

    TABLE 4: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031

    TABLE 5: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Geography, 2017–2031

    TABLE 6: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country, 2017–2031 

    TABLE 7: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

    TABLE 8: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031 

    TABLE 9: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031

    TABLE 10: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

    TABLE 11: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031

    TABLE 12: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031 

    TABLE 13: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

    TABLE 14: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031 

    TABLE 15: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031

    TABLE 16: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

    TABLE 17: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031

    TABLE 18: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031 

    TABLE 19: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

    TABLE 20: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031

    List of Figures

    FIG. 1: Comparative Analysis: Global 3D Printing Market, by Treatment, 2021 & 2028 (%)

    FIG. 2: Global Glioblastoma Multiforme Treatment (GBM) Market Segmentation

    FIG. 3: Global Glioblastoma Multiforme Treatment (GBM) Market, by Drug Class, 2020

    FIG. 4: Global Glioblastoma Multiforme Treatment (GBM) Market, by Treatment, 2020

    FIG. 5: Global Glioblastoma Multiforme Treatment (GBM) Market: Drivers and Restraints

    FIG. 6: Porter’s Five Forces Analysis for Glioblastoma Multiforme Treatment (GBM) Market

    FIG. 7: Market Attractiveness Analysis: Glioblastoma Multiforme Treatment (GBM) Market, by Region

    FIG. 8: Global Glioblastoma Multiforme Treatment (GBM) Market Share Analysis of Key Players

    FIG. 9: Global Glioblastoma Multiforme Treatment (GBM) Market Segmentation, by Drug Class

    FIG. 10: Global Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

    FIG. 11: Global Radiation Therapy Market Value (US$ Mn), 2021–2028

    FIG. 12: Global Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 13: Global Temozolomide Market Value (US$ Mn), 2021–2028

    FIG. 14: Global Bevacizumab Market Value (US$ Mn), 2021–2028

    FIG. 15: Global Lomustine Market Value (US$ Mn), 2021–2028

    FIG. 16: Global Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 17: Global Tumor Treating Field (TTF) Therapy Market, 2021–2028

    FIG. 18: Market Segmentation of Glioblastoma Multiforme Treatment (GBM) Market, by Drug Class

    FIG. 19: North America Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

    FIG. 20: North America Radiation Therapy Market Value (US$ Mn), 2021–2028

    FIG. 21: North America Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 22: North America Temozolomide Market Value (US$ Mn), 2021–2028

    FIG. 23: North America Bevacizumab Market Value (US$ Mn), 2021–2028

    FIG. 24: North America Lomustine Market Value (US$ Mn), 2021–2028

    FIG. 25: North America Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 26: North America Tumor Treating Field (TTF) Therapy Market, 2021–2028

    FIG. 27: Europe Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

    FIG. 28: Europe Radiation Therapy Market Value (US$ Mn), 2021–2028

    FIG. 29: Europe Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 30: Europe Temozolomide Market Value (US$ Mn), 2021–2028

    FIG. 31: Europe Bevacizumab Market Value (US$ Mn), 2021–2028

    FIG. 32: Europe Lomustine Market Value (US$ Mn), 2021–2028

    FIG. 33: Europe Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 34: Europe Tumor Treating Field (TTF) Therapy Market, 2021–2028

    FIG. 35: Asia Pacific Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

    FIG. 36: Asia Pacific Radiation Therapy Market Value (US$ Mn), 2021–2028

    FIG. 37: Asia Pacific Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 38: Asia Pacific Temozolomide Market Value (US$ Mn), 2021–2028

    FIG. 39: Asia Pacific Bevacizumab Market Value (US$ Mn), 2021–2028

    FIG. 40: Asia Pacific l Lomustine Market Value (US$ Mn), 2021–2028

    FIG. 41: Asia Pacific Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 42: Asia Pacific Tumor Treating Field (TTF) Therapy Market, 2021–2028

    FIG. 43: Latin America Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

    FIG. 44: Latin America Radiation Therapy Market Value (US$ Mn), 2021–2028

    FIG. 45: Latin America Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 46: Latin America Temozolomide Market Value (US$ Mn), 2021–2028

    FIG. 47: Latin America Bevacizumab Market Value (US$ Mn), 2021–2028

    FIG. 48: Latin America Lomustine Market Value (US$ Mn), 2021–2028

    FIG. 49: Latin America Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 50: Latin America Tumor Treating Field (TTF) Therapy Market, 2021–2028

    FIG. 51: Middle East & Africa Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

    FIG. 52: Middle East & Africa Radiation Therapy Market Value (US$ Mn), 2021–2028

    FIG. 53: Middle East & Africa Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 54: Middle East & Africa Temozolomide Market Value (US$ Mn), 2021–2028

    FIG. 55: Middle East & Africa Bevacizumab Market Value (US$ Mn), 2021–2028

    FIG. 56: Middle East & Africa Lomustine Market Value (US$ Mn), 2021–2028

    FIG. 57: Middle East & Africa Targeted Therapy Market Value (US$ Mn), 2021–2028

    FIG. 58: Middle East & Africa Tumor Treating Field (TTF) Therapy Market, 2021–2028

Copyright © Transparency Market Research, Inc. All Rights reserved